During the past decade, Klinikum Ernst von Bergmann, Frauenklinik conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Klinikum Ernst von Bergmann, Frauenklinik" are "Breast Cancer" (1 trials), "Fatigue" (1 trials), "Locally Advanced or Metastatic Breast Cancer" (1 trials) and "Triple-Negative Breast Cancer" (1 trials). Many other conditions were trialed in "Klinikum Ernst von Bergmann, Frauenklinik" in a lesser frequency.

Most popular intervention types in "Klinikum Ernst von Bergmann, Frauenklinik" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Atezolizumab" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody" (1 trials), "Atezolizumab Placebo" (1 trials) and "Paclitaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Klinikum Ernst von Bergmann, Frauenklinik" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Klinikum Ernst von Bergmann, Frauenklinik". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Klinikum Ernst von Bergmann, Frauenklinik, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Klinikum Ernst von Bergmann, Frauenklinik, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".